Welcome to AMYPAD!
We were a collaborative research initiative aiming to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of ß-amyloid PET imaging. AMYPAD was funded from October 2016 until September 2022.
The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) initiative aimed to:
- improve the diagnostic work-up of people suspected to have Alzheimer’s disease and their management
- understand the natural history of the disease in a pre-symptomatic stage
- select people for treatment trials aiming at preventing Alzheimer’s disease
|
|
|
Neuraceq™ (left) and Vizamyl™ (right). Upper images: amyloid negative scans. Lower images: amyloid positive scans.
Latest News
The primary manuscript of the AMYPAD Diagnostic Study is out
11 May 2023
The study showed that access to this diagnostic test resulted in an etiological diagnosis with very high certainty in 40% of patients......
AMYPAD at AAIC2023
11 Apr 2023
AMYPAD has the opportunity to hold a Featured Research Session at AAIC2023......
AMYPAD presents at AD/PD2023
03 Apr 2023
The conference was also a great opportunity for presenting AMYPAD......
"We would hope that the direct results of the project are useful about our thinking of when amyloid deposition starts and when it's clinically relevant. But what is even more important is that the consortium that we formed, started collaborating on things that go well beyond the initial goals of AMYPAD. And actually, we should further integrate AMYPAD, EPAD and all the European cohorts that are now collaborating and joining forces in analysis of PET/MRI scans, imaging, biomarker but also genetic data. It is something of great value and will contribute to the future of all samples, definitely in Europe and hopefully also globally. ” Frederik Barkhof
AMYPAD Project Coordinator and Professor of Neuroradiology at VU University Medical Centre, Amsterdam and at University College London.
